R2R Biofluidics hast started on February 1st, 2015. During the next 4 years it aims for the development of a complete process chain for first-time realization of production lines for two selected bioanalytical lab-on-chip devices based on high throughput R2R nanoimprinting in combination with complementary printing and manufacturing technologies. The consortium, consisting of high qualified experts in the fields of engineering and production technology, chemistry and materials development, and biotechnology and life sciences, will fabricate two types of demonstrators by realising a complete high-volume process chain for industrial fabrication of bioanalytical lab-on-chip devices based on setting–up a roll-to-roll (R2R) production line:
Demonstrator 1: In-vitro diagnostic chip with imprinted microfluidic channels based on chemiluminescence detection using photodetectors; containing imprinted optical nanostructures for light coupling and thus improving device performance.
Demonstrator 2: Cell-chips containing imprinted cavities and micro- to nanoscale channels for controlled neuron culturing to be applied in high throughput drug screening.
These types of demonstrators will target application areas, which will clearly benefit from technology advancement in high volume manufacturing, show large potential for commercial exploitation and adopt current standard formats (microtiter plate and microscope slides).
Role of the BioNanoNet Forschungsgesellschaft mbH in the “R2R Biofluidics” project:
Within “R2R Biofluidics”, the BioNanoNet Forschungsgesellschaft mbH is responsible for the day-to-day management of the whole project. As a part of the Project Management Team, it supports the Project Coordinator (JOANNEUM RESEARCH MATERIALS – Institute for Surface Technologies and Photonics) in all administrative issues as well as dissemination activities.
Moreover, BioNanoNet is responsible for the evaluation of potential hazards and safety issues during the production of microfluidic lab-on-chip devices as well as regulatory issues, and is closely working together with Tecnalia Research & Innovation, which carries out biocompatibility and cytotoxicity studies of the coating and resist materials used in the project following the protocols described in the ISO 10993 standard.
By implementing its safety strategy, the overall aim by BioNanoNet’s nanosafety team is to ensure that all aspects of the involved processes will be conform to the “Safe by Design” concept for the technological development.
For more details please visit the project website http://www.r2r-biofluidics.eu